Personale

Recapiti

Orario di ricevimento

Italiano

Biografia

Curriculum

Interessi

Pubblicazioni

Insegnamenti

English

Biography

Curriculum

Interest

Stefania NOBILI

Ruolo attuale:: Ricercatore Legge 240/10 a tempo determinato
SSD:: BIOS-11/A - Farmacologia
Afferenza organizzativa:: Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino (NEUROFARBA)

Recapiti

	0552758312
	stefania.nobili(AT)unifi.it

Stefania NOBILI

Curriculum

La Dott.ssa Stefania Nobili ha conseguito la Laurea in Farmacia nel 1989 (Università “La Sapienza”, Roma), la Specializzazione in Farmacologia Applicata nel 1997 (Università di Firenze) e il Dottorato di Ricerca in Chemioterapia nel 2002 (Università di Milano).

Dall’ottobre 2022, la Dr. Nobili è Ricercatore (RTD B) in Farmacologia (ex BIO/14, ora BIOS-11A) presso il Dipartimento NEUROFARBA dell'Università di Firenze.

Dal 2020 al 2022 è stata Ricercatore (RTD B, BIO/14) presso l'Università “G. d'Annunzio” di Chieti-Pescara (Chieti) e negli anni precedenti (2007-2019) è stata Ricercatore (RTD e RTD-A BIO/14) presso l'Università di Firenze.

Tra i principali riconoscimenti ottenuti negli ultimi anni ci sono l'abilitazione scientifica nazionale (ASN) a Professore Ordinario in Farmacologia (BIOS-11A) (2023) e la vincita di un posto di Ricercatore (RTD-B) in Farmacologia (BIO/14) presso l'Università di Genova (2021). Inoltre, la Dott.ssa Nobili possiede l'ASN come Professore Associato in Farmacologia (2014 e 2018), come Professore Associato per il settore 06/N1 Scienze delle Professioni Sanitarie e Tecnologie Mediche Applicate, SSD MED/46 Scienze Tecniche di Medicina di Laboratorio (2018) e come Professore Associato per il settore 06/D3 Malattie Ematologiche, Oncologia e Reumatologia, SSD MED/06 Oncologia (2018).

Ha ricevuto i seguenti premi: Premio “Alberico Benedicenti” per la Farmacologia e Tossicologia (Società Italiana di Farmacologia, 2013); Premio “Emilio Trabucchi” (Società Italiana di Chemioterapia, 2009).

La Dott.ssa Nobili è membro della Commissione di Eccellenza del Dipartimento NEUROFARBA (Dipartimento di Eccellenza 2023-2027) e membro del Comitato Scientifico della Biblioteca Biomedica dell'Università di Firenze.

È membro della Società Italiana di Farmacologia (SIF) e dei seguenti tre gruppi di lavoro SIF: Farmacologia Oncologica, Farmacogenetica, Farmacologia Pediatrica.

È segretario della Società Italiana di Chemioterapia (SIC) e liaison tra il PathoBiology Group (PBG) e il Pharmacology and Molecular Mechanisms (PAMM) Group dell'European Organization for Research and Treatment of Cancer (EORTC).

La Dott.ssa Nobili è stata relatore e co-relatore delle tesi di diversi studenti presso l'Università di Firenze ed è attualmente supervisore o co-supervisore di due dottorandi.

È membro del Collegio dei Docenti del Corso di Dottorato di Ricerca in Area del Farmaco e Trattamenti Innovativi dell'Università di Firenze. Attualmente insegna farmacologia agli studenti del corso di Laurea in Odontoiatria e Protesi Dentaria e farmacologia e tossicologia agli studenti del corso di Laurea in Infermieristica. Insegna farmacologia anche presso le Scuole di Specializzazione in “Farmacologia Clinica e Tossicologia” e “Oncologia Medica” (Università di Firenze).

L'attività didattica principale negli anni precedenti è stata rappresentata dal corso di chemioterapia per gli studenti di Farmacia (Università di Firenze), dai corsi di farmacologia per gli studenti di Infermieristica (Università di Firenze e Università “G. d'Annunzio” di Chieti-Pescara), per gli studenti di Biotecnologie, per gli studenti delle scuole di specializzazione in Farmacia Ospedaliera e di varie scuole di specializzazione di area medica presso l'Università di Firenze e l'Università 2G. d'Annunzio" di Chieti-Pescara.

La Dott.ssa Nobili partecipa regolarmente a convegni nazionali e internazionali in qualità di relatore su invito (25 relazioni su invito).

La Dott.ssa Nobili ha ottenuto finanziamenti da istituzioni (ad es. Università di Firenze, Università “G. d'Annunzio” di Chieti-Pescara, ANVUR-MIUR) e da enti e fondazioni locali, nazionali/internazionali (EUniWell, Regione Toscana, Fondazione Cassa di Risparmio di Firenze, ThermoFisher Scientific (US), Giacomo ODV).

È Editore di Sezione per la farmacologia e la farmaceutica per il giornale All Life (Taylor & Francis, UK), Editore associato per BMC Pharmacology & Toxicology (Springer Nature, UK), Frontiers in Pharmacology (Frontiers Media SA, Svizzera), Frontiers in Oncology (Frontiers Media SA, Svizzera), Editore per Archives of Natural and Medicinal Chemistry (Gavin Publishers, USA). Inoltre, la Dott.ssa Nobili si occupa regolarmente della revisione di articoli sulla farmacologia del cancro e di area oncologica.

Svolge ruolo di valutatore ANVUR e di esperto per la valutazione di progetti presentati ad agenzie nazionali (Università di Modena e Reggio Emilia) e internazionali (ad es., Progetti Europei H2020, Bruxelles, Belgio; Programma H2020-Marie Skłodowska-Curie COFUND (NL); Fondazione “La Caixa”, Barcellona, Spagna; Koningin Wilhelmina Fonds (KWF) Dutch Cancer Society, (NL); Natural Sciences and Engineering Research Council of Canada, Ottawa, Canada).

I suoi interessi di ricerca si concentrano sulla farmacologia preclinica e clinica dei farmaci antitumorali, in particolare sulla farmacogenetica e farmacogenomica del cancro e sulla resistenza ai farmaci antitumorali. Anche gli agenti antimicrobici, con particolare riferimento agli antibiotici, rappresentano un campo di interesse.

È responsabile dei dataset GSE122246 e GSE186441 disponibili sul sito NCBI GEO (Gene Expression Omnibus).

La Dott.ssa Nobili ha pubblicato oltre 100 articoli peer-reviewed su riviste internazionali e 35 capitoli di libri (Scopus: citazioni totali 4860; HI 34).

Stefania NOBILI

Pubblicazioni

Legenda

Contributo su rivista |

Articolo su libro |

Libro |

Contributo in atti di convegno (proceeding) |

Brevetto |

Curatela | Altro

Altro |

Tesi di Dottorato

Perrone, Gabriele; Rigacci, Luigi; Roviello, Giandomenico; Landini, Ida; Fabbri, Alberto; Iovino, Lorenzo; Puccini, Benedetta; Cencini, Emanuele; Orciuolo, Enrico; Bocchia, Monica; Bosi, Alberto; Mini, Enrico; Nobili, Stefania (2024). Validation of single nucleotide polymorphisms potentially related to R-CHOP resistance in diffuse large B-cell lymphoma patients. CANCER DRUG RESISTANCE, vol. 7, pp. 1-14, ISSN:2578-532X DOI

Askari M.; Mirzaei E.; Navapour L.; Karimpour M.; Rejali L.; Sarirchi S.; Nazemalhosseini-Mojarad E.; Nobili S.; Cava C.; Sadeghi A.; Fatemi N. (2024). Integrative Bioinformatics Analysis: Unraveling Variant Signatures and Single-Nucleotide Polymorphism Markers Associated with 5-FU-Based Chemotherapy Resistance in Colorectal Cancer Patients. JOURNAL OF GASTROINTESTINAL CANCER, vol. 55, pp. 1607-1619, ISSN:1941-6628 DOI

Patrignani P.; Tacconelli S.; Contursi A.; Piazuelo E.; Bruno A.; Nobili S.; Mazzei M.; Milillo C.; Hofling U.; Hijos-Mallada G.; Sostres C.; Lanas A. (2024). Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action. FRONTIERS IN PHARMACOLOGY, vol. 15, pp. 1-18, ISSN:1663-9812 DOI

Nobili, Stefania; Micheli, Laura; Lucarini, Elena; Toti, Alessandra; Ghelardini, Carla; Di Cesare Mannelli, Lorenzo (2024). Ultramicronized N-palmitoylethanolamine associated with analgesics: Effects against persistent pain. PHARMACOLOGY & THERAPEUTICS, vol. 258, pp. 0-0, ISSN:0163-7258 DOI

Micheli, Laura; Nobili, Stefania; Lucarini, Elena; Toti, Alessandra; Margiotta, Francesco; Ciampi, Clara; Venturi, Daniel; Di Cesare Mannelli, Lorenzo; Ghelardini, Carla (2024). New insights in the mechanisms of opioid analgesia and tolerance: Ultramicronized palmitoylethanolamide down-modulates vascular endothelial growth factor-A in the nervous system. PHARMACOLOGICAL RESEARCH, vol. 209, pp. 0-0, ISSN:1043-6618 DOI

Micheli, Laura; Muraglia, Marilena; Corbo, Filomena; Venturi, Daniel; Clodoveo, Maria Lisa; Tardugno, Roberta; Santoro, Valentina; Piccinelli, Anna Lisa; Di Cesare Mannelli, Lorenzo; Nobili, Stefania; Ghelardini, Carla (2024). The Unripe Carob Extract (Ceratonia siliqua L.) as a Potential Therapeutic Strategy to Fight Oxaliplatin-Induced Neuropathy. NUTRIENTS, vol. 17, pp. 0-0, ISSN:2072-6643 DOI

Perrone, Gabriele; Rigacci, Luigi; Urru, Sara; Kovalchuk, Sofya; Brugia, Marco; Fabbri, Alberto; Iovino, Lorenzo; Puccini, Benedetta; Cencini, Emanuele; Orciuolo, Enrico; Birtolo, Silvia; Melosi, Alessandro; Santini, Simone; Landini, Ida; Roviello, Giandomenico; Santi, Raffaella; Macciotta, Alessandra; Ricceri, Fulvio; Bosi, Alberto; Bocchia, Monica; Petrini, Mario; Mini, Enrico; Nobili, Stefania (2023). Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma. CANCERS, vol. 15, pp. 0-0, ISSN:2072-6694 DOI

Catalano, Martina; Lapucci, Andrea; Nobili, Stefania; De Gennaro Aquino, Irene; Vascotto, Ismaela Anna; Antonuzzo, Lorenzo; Villari, Donata; Nesi, Gabriella; Mini, Enrico; Roviello, Giandomenico (2023). Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?. CANCER CHEMOTHERAPY AND PHARMACOLOGY, pp. 0-0, ISSN:0344-5704 DOI

Catalano, Martina; Iannone, Luigi Francesco; Nesi, Gabriella; Nobili, Stefania; Mini, Enrico; Roviello, Giandomenico (2023). Immunotherapy-related biomarkers: Confirmations and uncertainties. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 192, pp. 104135-104136, ISSN:1040-8428 DOI

Rejali, Leili; Seifollahi Asl, Romina; Sanjabi, Fatemeh; Fatemi, Nayeralsadat; Asadzadeh Aghdaei, Hamid; Saeedi Niasar, Mahsa; Ketabi Moghadam, Pardis; Nazemalhosseini Mojarad, Ehsan; Mini, Enrico; Nobili, Stefania (2023). Principles of Molecular Utility for CMS Classification in Colorectal Cancer Management. CANCERS, vol. 15, pp. 0-0, ISSN:2072-6694 DOI

Lavacchi D.; Landini I.; Perrone G.; Roviello G.; Mini E.; Nobili S. (2022). Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge. PHARMACOLOGY & THERAPEUTICS, vol. 229, pp. 1-16, ISSN:0163-7258 DOI Accesso ONLINE all'editore

Micheli, Laura; Lucarini, Elena; Nobili, Stefania; Bartolucci, Gianluca; Pallecchi, Marco; Toti, Alessandra; Ferrara, Valentina; Ciampi, Clara; Ghelardini, Carla; Di Cesare Mannelli, Lorenzo (2022). Ultramicronized N-palmitoylethanolamine contributes to morphine efficacy against neuropathic pain: implication of mast cells and glia. CURRENT NEUROPHARMACOLOGY, vol. 21, pp. 0-0, ISSN:1570-159X DOI

Nobili, Stefania; Mini, Enrico (2022). Special Issue: “Gastrointestinal Cancers and Personalized Medicine”. JOURNAL OF PERSONALIZED MEDICINE, vol. 12, pp. 338-343, ISSN:2075-4426 DOI

Parsa, Fatemeh Ghorbani; Nobili, Stefania; Karimpour, Mina; Aghdaei, Hamid Asadzadeh; Nazemalhosseini-Mojarad, Ehsan; Mini, Enrico (2022). Fanconi Anemia Pathway in Colorectal Cancer: A Novel Opportunity for Diagnosis, Prognosis and Therapy. JOURNAL OF PERSONALIZED MEDICINE, vol. 12, pp. 396-421, ISSN:2075-4426 DOI

Russo, Valentina; Lallo, Eleonora; Munnia, Armelle; Spedicato, Miriana; Messerini, Luca; D'Aurizio, Romina; Ceroni, Elia Giuseppe; Brunelli, Giulia; Galvano, Antonio; Russo, Antonio; Landini, Ida; Nobili, Stefania; Ceppi, Marcello; Bruzzone, Marco; Cianchi, Fabio; Staderini, Fabio; Roselli, Mario; Riondino, Silvia; Ferroni, Patrizia; Guadagni, Fiorella; Mini, Enrico; Peluso, Marco (2022). Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. CANCERS, vol. 14, pp. 4012-4049, ISSN:2072-6694 DOI

Lapucci, Andrea; Perrone, Gabriele; Di Paolo, Antonello; Napoli, Cristina; Landini, Ida; Roviello, Giandomenico; Calosi, Laura; Naccarato, Antonio Giuseppe; Falcone, Alfredo; Bani, Daniele; Mini, Enrico; Nobili, Stefania (2021). PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients. ONCOLOGY RESEARCH, vol. 28, pp. 631-644, ISSN:0965-0407 DOI

Altavilla A, Mini E, Nobili S, Santarpia M (2021). Effetti collaterali dei trattamenti antitumorali: chemioterapia e terapia orale. In: Massimo Aglietta. Oncologia Medica, II edizione, pp. 66-79 Edizioni Minerva Medica spa, ISBN:9788855320948.

Peyravian N.; Nobili S.; Pezeshkian Z.; Olfatifar M.; Moradi A.; Baghaei K.; Anaraki F.; Nazari K.; Aghdaei H.A.; Zali M.R.; Mini E.; Mojarad E.N. (2021). Increased expression of vangl1 is predictive of lymph node metastasis in colorectal cancer: Results from a 20-gene expression signature. JOURNAL OF PERSONALIZED MEDICINE, vol. 11, pp. 1-22, ISSN:2075-4426 DOI

Angelini, S.; Cecchin, E.; Conti, V.; Dal Piaz, F.; Filippelli, A.; Hrelia, P.; Landini, I.; Menna, P.; Mini, E.; Nobili, S.; Soledad Poetto, A.; Ravegnini, G.; Roncato, R.; Minotti, G. (2021). Therapeutic drug monitoring for the cancer patient: challenges and opportunities. PHARMADVANCES, vol. 3, pp. 592-600 DOI

Nobili S.; Lucarini E.; Murzilli S.; Vanelli A.; Di Cesare Mannelli L.; Ghelardini C. (2021). Efficacy evaluation of plant products in the treatment of erectile dysfunction related to diabetes. NUTRIENTS, vol. 13, pp. 4520-4520, ISSN:2072-6643 DOI

Roviello G.; Rodriquenz M.G.; Aprile G.; D'Angelo A.; Roviello F.; Nobili S.; Mini E.; Sarno I.; Polom K. (2021). Maintenance in gastric cancer: New life for an old issue?. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 160, pp. 103307-103315, ISSN:1040-8428 DOI

Pezeshkian Z.; Nobili S.; Peyravian N.; Shojaee B.; Nazari H.; Soleimani H.; Asadzadeh-Aghdaei H.; Bonab M.A.; Nazemalhosseini-Mojarad E.; Mini E. (2021). Insights into the role of matrix metalloproteinases in precancerous conditions and in colorectal cancer. CANCERS, vol. 13, pp. 6226-6245, ISSN:2072-6694 DOI

Nobili, Stefania; Mannini, Antonella; Parenti, Astrid; Raggi, Chiara; Lapucci, Andrea; Chiorino, Giovanna; Paccosi, Sara; Di Gennaro, Paola; Vezzosi, Vania; Romagnoli, Paolo; Susini, Tommaso; Coronnello, Marcella (2021). Establishment and characterization of a new spontaneously immortalized ER-/PR-/HER2+ human breast cancer cell line, DHSF-BR16. SCIENTIFIC REPORTS, vol. 11, pp. 8340-8354, ISSN:2045-2322 DOI Accesso ONLINE all'editore

Roncato, R.; Cecchini, E.; Dalle Fratte, C.; Decorti, G.; Del Re, M.; Franca, R.; Nobili, S.; Ravegnini, G.; Stocco, G.; Mini, E.; Toffoli, G.; Cancer Pharmacology Working Group, W.G. (2021). Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers. PHARMADVANCES, vol. 3, pp. 357-368 DOI

Roviello G.; Fancelli S.; Gatta Michelet M.R.; Aprile G.; Nobili S.; Roviello F.; Cianchi F.; Mini E.; Lavacchi D. (2020). TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 152, pp. 1-9, ISSN:1040-8428 DOI

Roviello G.; Casadei-Gardini A.; Nobili S.; Mini E.; Fancelli S. (2020). Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment. JOURNAL OF ONCOLOGY, vol. 2020, pp. 1-4, ISSN:1687-8450 DOI

Catalano, Martina; Roviello, Giandomenico; Conca, Raffaele; D’Angelo, Alberto; Palmieri, Valeria Emma; Panella, Benedetta; Petrioli, Roberto; Ianza, Anna; Nobili, Stefania; Mini, Enrico; Ramello, Monica (2020). Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study. CURRENT CANCER DRUG TARGETS, vol. 20, pp. 0-0, ISSN:1568-0096 DOI Accesso ONLINE all'editore

D'Angelo A.; Bagby S.; Di Pierro G.; Chirra M.; Nobili S.; Mini E.; Villari D.; Roviello G. (2020). An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC). CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 149, pp. 10921-10921, ISSN:1040-8428 DOI

Roviello G.; Corona S.P.; D'angelo A.; Rosellini P.; Nobili S.; Mini E. (2020). Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, pp. 448-448, ISSN:1661-6596 DOI

Roviello G.; D'Angelo A.; Sciortino M.; Mini E.; Nobili S.; De Logu F.; Massi D. (2020). TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 152, pp. 0-0, ISSN:1040-8428 DOI

Roviello G.; Ramello M.; Catalano M.; D'Angelo A.; Conca R.; Gasperoni S.; Dreoni L.; Petrioli R.; Ianza A.; Nobili S.; Aieta M.; Mini E. (2020). Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. SCIENTIFIC REPORTS, vol. 10, pp. 19281-19289, ISSN:2045-2322 DOI

Mini Enrico; Nobili Stefania (2020). Pharmacogenetics of Cancer. CANCER DRUG RESISTANCE, pp. 0-0, ISSN:2578-532X DOI

Nobili, Stefania; Lavacchi, Daniele; Perrone, Gabriele; Vicini, Giulio; Tassi, Renato; Landini, Ida; Grosso, AnnaMaria; Roviello, Giandomenico; Mazzanti, Roberto; Santomaggio, Carmine; Mini, Enrico (2020). Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience. ONCOLOGY RESEARCH, pp. 237-248, ISSN:0965-0407 DOI

Landini, Ida; Massai, Lara; Cirri, Damiano; Gamberi, Tania; Paoli, Paolo; Messori, Luigi; Mini, Enrico; Nobili, Stefania (2020). Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties. JOURNAL OF INORGANIC BIOCHEMISTRY, vol. 208, pp. 0-0, ISSN:0162-0134 DOI

Nobili S, Lapucci A, Landini I, Coronnello M, Roviello G, Mini E. (2020). Role of ATP-binding cassette transporters in cancer initiation and progression. SEMINARS IN CANCER BIOLOGY, pp. 72-95, ISSN:1044-579X DOI

Adembri, Chiara; Novelli, Andrea; Nobili, Stefania (2020). Some Suggestions from PK/PD Principles to Contain Resistance in the Clinical Setting-Focus on ICU Patients and Gram-Negative Strains. ANTIBIOTICS, vol. 9, pp. 676-686, ISSN:2079-6382 DOI

Roviello, Giandomenico; Catalano, Martina; Nobili, Stefania; Santi, Raffaella; Mini, Enrico; Nesi, Gabriella (2020). Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, pp. 7935-7943, ISSN:1422-0067 DOI

Giandomenico Roviello, Alberto D'Angelo, Roberto Petrioli, Franco Roviello, Fabio Cianchi, Stefania Nobili, Enrico Mini, Daniele Lavacchi (2020). Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. TRANSLATIONAL ONCOLOGY, pp. 0-0, ISSN:1936-5233 DOI

Roviello, G; Gatta Michelet, M R; D'Angelo, A; Nobili, S; Mini, E (2019). Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials. CLINICAL & TRANSLATIONAL ONCOLOGY, pp. 1-7, ISSN:1699-048X DOI

Roviello G.; Nobili S.; Mini E. (2019). A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical development. JOURNAL OF CHEMOTHERAPY, vol. 31, pp. 295-296, ISSN:1120-009X DOI Accesso ONLINE all'editore

Roviello G, Conter FU, Mini E, Generali D, Traversini M, Lavacchi D, Nobili S, Sobhani N. (2019). Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer.. CANCER CHEMOTHERAPY AND PHARMACOLOGY, pp. 0-10, ISSN:0344-5704

Mini E.; Lapucci A.; Perrone G.; D'Aurizio R.; Napoli C.; Brugia M.; Landini I.; Tassi R.; Picariello L.; Simi L.; Mancini I.; Messerini L.; Magi A.; Pinzani P.; Mazzei T.; Tonelli F.; Nobili S. (2019). RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. INTERNATIONAL JOURNAL OF CANCER, pp. 0-0, ISSN:0020-7136, Wiley-Liss Inc.: DOI Accesso ONLINE all'editore

Tiziano Marzo, Lara Massai, Alessandro Pratesi, Matteo Stefanini, Damiano Cirri, Francesca Magherini, Matteo Becatti, Ida Landini, Stefania Nobili, Enrico Mini, Olivia Crociani, Annarosa Arcangeli, Serena Pillozzi, Tania Gamberi, Luigi Messori (2019). Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer. ACS MEDICINAL CHEMISTRY LETTERS, vol. 10 (4), pp. 656-660, ISSN:1948-5875, American Chemical Society: DOI Accesso ONLINE all'editore

Toffoli G, Innocenti F, Polesel J, De Mattia E, Sartor F, Fratte CD, Ecca F, Dreussi E, Palazzari E, Guardascione M, Buonadonna A, Foltran L, Garziera M, Bignucolo A, Nobili S, Mini E, Favaretto A, Berretta M, D'Andrea M, De Paoli A, Roncato R, Cecchin E. (2019). The genotype for DPYD risk variants in colorectal cancer patients and the related toxicity management costs in clinical practice.. CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. ..., pp. 1-27, ISSN:1532-6535 DOI

Altavilla G, Mini E, Nobili S, Ostuni C, Santarpia M, Silvestris, F (2018). Principali effetti collaterali delle terapie mediche. In: Collegio degli Oncologi Medici Italiani. Manuale di Oncologia Medica, pp. 94-108, Torino: Edizioni Minerva Medica spa, ISBN:9788877119391.

F Ecca, E De Mattia, F Serra, R Roncato, E Dreussi, L Romanato, A Buonadonna, A De Paoli, M Berretta, E Mini, S Nobili, G Toffoli, E Cecchin (2018). Next-Generation Sequencing to Identify Rare Variants Related to FL-Toxicity. PUBLIC HEALTH GENOMICS, vol. 21, pp. 19-19, ISSN:1662-8063 DOI

Dalle Fratte C, Polesel J, Roncato R, De Mattia E, Ecca F, Bignucolo A, Garziera M, Dreussi E, Palazzari E, Buonadonna A, Guardascione M, Berretta M, Foltran L, Sartor F, D’Andrea M, Favaretto A, Mini E, Nobili S, De Paoli A, Toffoli G, Cecchin E. (2018). DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients. JOURNAL OF MOLECULAR AND CLINICAL MEDICINE, vol. 1, pp. 143-150, ISSN:2616-3632 DOI

Mini, Enrico; Landini, Ida; Lucarini, Laura; Lapucci, Andrea; Napoli, Cristina; Perrone, Gabriele; Tassi, Renato; Masini, Emanuela; Moroni, Flavio; Nobili, Stefania (2018). Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616). ONCOLOGY RESEARCH, vol. 26, pp. 333-334, ISSN:0965-0407 DOI Accesso ONLINE all'editore

Magherini, Francesca; Fiaschi, Tania; Valocchia, Elisa; Becatti, Matteo; Pratesi, Alessandro; Marzo, Tiziano; Massai, Lara; Gabbiani, Chiara; Landini, Ida; Nobili, Stefania; Mini, Enrico; Messori, Luigi; Modesti, Alessandra; Gamberi, Tania* (2018). Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study. ONCOTARGET, vol. 9, pp. 28042-28068, ISSN:1949-2553 DOI Accesso ONLINE all'editore

De Mattia E, Dreussi E, Montico M, Gagno S, Zanusso C, Quartuccio L, De Vita S, Guardascione M, Buonadonna A, D'Andrea M, Pella N, Favaretto A, Mini E, Nobili S, Romanato L, Cecchin E, Toffoli G. (2018). A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy.. FRONTIERS IN PHARMACOLOGY, vol. 9, pp. 1-12, ISSN:1663-9812 DOI

Lavacchi D, Nobili S, Brugia M, Paderi A, Fancelli S, Caliman E, Vergoni F, Mini E. (2018). A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma.. BMC CANCER, vol. 18, pp. 1-5, ISSN:1471-2407 DOI

Villanucci A, Tavella K, Vannini L, Rossi V, Nobili S, Amunni G, Mazzei T, Mini E (2018). Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors. MOLECULAR AND CLINICAL ONCOLOGY, vol. 9, pp. 635-639, ISSN:2049-9450 DOI

Santi, Raffaella; Cai, Tommaso; Nobili, Stefania; Galli, Ilaria Camilla; Amorosi, Andrea; Comperat, Eva; Nesi, Gabriella (2018). Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study. VIRCHOWS ARCHIV, pp. 1-9, ISSN:0945-6317 DOI Accesso ONLINE all'editore

Allen WL, Dunne PD, McDade S, Scanlon E, Loughrey M, Coleman H, McCann C, McLaughlin K, Nemeth Z, Syed N, Jithesh P, Arthur K, Wilson R, Coyle V, McArt D, Murray GI, Samuel L, Nuciforo P, Jimenez J, Argiles G, Dienstmann R, Tabernero J, Messerini L, Nobili S, Mini E, Sheahan K, Ryan E, Johnston PG, Van Schaeybroeck S, Lawler M, Longley DB. (2018). Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy.. JCO PRECISION ONCOLOGY, vol. ...., pp. 1-31, ISSN:2473-4284 DOI

Mini, E; Landini, I; Lucarini, L; Lapucci, A; Napoli, C; Perrone, G; Tassi, R; Masini, E; Moroni, F; Nobili, S. (2017). The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways.. ONCOLOGY RESEARCH, vol. 25, pp. 1441-1451, ISSN:0965-0407 DOI

S Kovalchuk, L Rigacci, G Perrone, S Nobili, B Puccini, R Tassi, M Brugia, I Landini, L Mannelli, G Benelli, C Napoli, E Cencini, A Fabbri, L Iovino, M Petrini, S Birtolo, A Melosi, S Santini, P Bernardeschi, A Bosi, E Mini (2017). THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY. HAEMATOLOGICA, vol. 102, pp. 27-27, ISSN:0390-6078

Mini E, Nobili S, Mazzei T (2017). Farmaci antineoplastici: Farmaci antiormonali.. In: Vari. Farmacologia – Principi di base e applicazioni terapeutiche - III edizione, pp. 878-886 Edizioni Minerva Medica, ISBN:978-88-7711-881-3.

Mini E, Nobili S, Mazzei T (2017). Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale - Farmaci inibitori di protein chinasi. In: Vari. Farmacologia – Principi di base e applicazioni terapeutiche - III edizione, pp. 889-902, Torino: Edizioni Minerva Medica, ISBN:978-88-7711-881-3.

Mini E, Nobili S, Mazzei T (2017). Farmaci antineoplastici - Farmaci immunoterapici - Anticorpi monoclonali inibitori dei checkpoints immunitari. In: Vari. Farmacologia – Principi di base e applicazioni terapeutiche - III edizione, pp. 908-910, Torino: Edizioni Minerva Medica, ISBN:978-88-7711-881-3.

Nobili S, Mini, E, Mazzei T, Vannacci A (2017). Adverse drug reactions in oncoLogy: intEnsive monitoring program on biotechnological anD taRget therapies in Oncologic patientS-ALEXANDROS observational study. DRUG SAFETY, vol. 40, pp. 993-993, ISSN:0114-5916

L. Rigacci; G. Perrone; S. Nobili; S. Kovalchuk; B. Puccini; R. Tassi; M. Brugia; I. Landini; L. Mannelli; G. Benelli; C. Napoli; E. Cencini; A. Fabbri; L. Iovino; M. Petrini; S. Birtolo; A. Melosi; S. Santini; P. Bernardeschi; A. Bosi; E. Mini (2017). Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study.. HAEMATOLOGICA, vol. 102, pp. 574-574, ISSN:0390-6078

Mini E, Nobili S, Mazzei T (2017). Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale - Generalità. In: Vari. Farmacologia – Principi di base e applicazioni terapeutiche - III edizione, pp. 887-889, Torino: Edizioni Minerva Medica, ISBN:978-88-7711-881-3.

Mini E., Nobili S., Mazzei T. (2017). Farmaci antineoplastici - Antimetaboliti. In: Vari. Farmacologia – Principi di base e applicazioni terapeutiche - III edizione, pp. 854-869 Edizioni Minerva Medica, ISBN:978-88-7711-881-3.

Maggini V, Gallo E, Landini I, Lapucci A, Nobili S, Mini E, Firenzuoli F (2017). P118 A preliminary study for evaluation of cannabis - chemotherapy interactions on human colon cancer cells. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 17, pp. 115-115, ISSN:1472-6882 DOI

Galiulo M, Convertino I, Blandizzi C, Tassi R, Diacciati S, Nobili S, Capogrosso Sansone A, Marino A, Mini E, Mazzei T, Vannacci A, Parrilli M, Corona T, Tuccori M (2017). Adverse drug reactions in oncoLogy: intEnsive monitoring program on drug toXicity of biotechnological medicatioNs anD taRget therapies in Oncologic patientS - the ALEXANDROS observational study. DRUG SAFETY, vol. 40, pp. 993-993, ISSN:0114-5916 DOI

Rigacci, L; Perrone, G; Nobili, S; Kovalchuk, S; Puccini, B; Tassi, R; Brugia, M; Landini, I; Mannelli, L; Benelli, G; Napoli, C; Cencini, E; Fabbri, A; Iovino, L; Petrini, M; Birtolo, S; Melosi, A; Santini, S; Bernardeschi, P; Bosi, A; Mini, E (2017). Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study.. HEMATOLOGICAL ONCOLOGY, vol. 35, pp. 291-292, ISSN:1099-1069 DOI

Landini, I; Lapucci, A; Pratesi, A; Massai, L; Napoli, C; Perrone, G; Pinzani, P; Messori, L; Mini, E; Nobili, S. (2017). Selection and characterization of a human ovarian cancer cell line resistant to auranofin. ONCOTARGET, vol. 8, pp. 96062-96078, ISSN:1949-2553

Mini E., Nobili S., Novelli A., Mazzei T. (2017). Farmaci antimicrobici - Glicopeptidi. In: Vari. Farmacologia – Principi di base e applicazioni terapeutiche - III edizione, pp. 737-745, Torino: Edizioni Minerva Medica, ISBN:978-88-7711-881-3.

Mini, E.; D’ Aurizio, R.; Perrone, G.; Magi, A.; Lapucci, A.; Tassi, R.; Napoli, C.; Picariello, L.; Landini, I.; Nobili, S. (2016). RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. EUROPEAN JOURNAL OF CANCER, vol. 61, pp. S199-S199, ISSN:0959-8049 DOI

Tassi, R.; Mini, E.; D'Aurizio, R.; Perrone, G.; Magi, A.; Lapucci, A.; Napoli, C.; Picariello, L.; Brugia, M.; Landini, I.; Mazzei, T.; Tonelli, F.; Nobili, S. (2016). D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. ANNALS OF ONCOLOGY, vol. 27, pp. iv43-iv43, ISSN:0923-7534 DOI

Mini E, Nobili S, Novelli A, Mazzei T (2016). GLICOPEPTIDI. In: Vincenzo Cuomo, Carlo Riccardi, Francesco Rossi. Farmacologia. Principi di base e applicazioni terapeutiche, pp. 737-744, Torino: Edizioni Minerva Medica spa, ISBN:9788877118813.

Tassi, R; Mini, E; D'Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Napoli, C; Picariello, L; Brugia, M; Landini, I; Mazzei, T; Tonelli, F; Nobili, S (2016). Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. ANNALS OF ONCOLOGY, vol. 27, pp. 43-43, ISSN:0923-7534 DOI

Garziera, M; Catamo, E; Crovella, S; Montico, M; Cecchin, E; Lonardi, S; Mini, E; Nobili, S; Romanato, L; Toffoli, G (2016). Association of the HLA-G 3′UTR polymorphisms with colorectal cancer in Italy: a first insight. INTERNATIONAL JOURNAL OF IMMUNOGENETICS, vol. 43, pp. 32-39, ISSN:1744-3121 DOI

Mini, E; Landini, I; Napoli, C; Nobili, S; Perrone, G; Lapucci, A (2016). Pharmacological modulation of protein kinase C for overcoming drug resistance in colorectal cancer. Preliminary results of in vitro studies.. ANNALS OF ONCOLOGY, vol. 27, pp. 45-45, ISSN:0923-7534 DOI

Mini, E; D’Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Tassi, R; Napoli, C; Picariello, L; Landini, I; Brugia, M; Mazzei, T; Tonelli, F; Nobili, S (2016). A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. ANNALS OF ONCOLOGY, vol. 27, pp. 575-575, ISSN:0923-7534 DOI

Tassi, R; Perrone, G; Brugia, M; Simi, L; Petreni, P; Mori, E; Landini, I; Pazzagli, M; Mazzei, T; Mini, E; Nobili, S (2015). Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors.. ANNALS OF ONCOLOGY, vol. 26, pp. 43-44, ISSN:0923-7534 DOI

Garziera, M; Bidoli, E; Cecchin, E; Mini, E; Nobili, S; Lonardi, S; Buonadonna, A; Errante, D; Pella, N; D'Andrea, M; De Marchi, F; De Paoli, A; Zanusso, C; De Mattia, E; Tassi, R; Toffoli, G. (2015). HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. PLOS ONE, vol. 10, pp. 1-17, ISSN:1932-6203 DOI

Toffoli, G; Giodini, L; Buonadonna, A; Berretta, M; De Paoli, A; Scalone, S; Miolo, G; Mini, E; Nobili, S; Lonardi, S; Pella, N; Lo Re, G; Montico, M; Roncato, R; Dreussi, E; Gagno, S; Cecchin, E. (2015). Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.. INTERNATIONAL JOURNAL OF CANCER, vol. 137, pp. 2971-2980, ISSN:0020-7136 DOI

Gamberi, Tania; Magherini, Francesca; Fiaschi, Tania; Landini, Ida; Massai, Lara; Valocchia, Elisa; Bianchi, Laura; Bini, Luca; Gabbiani, Chiara; Nobili, Stefania; Mini, Enrico; Messori, Luigi; Modesti, Alessandra (2015). Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication. MOLECULAR BIOSYSTEMS, vol. 11, pp. 1653-1667, ISSN:1742-206X DOI Accesso ONLINE all'editore

Cialdai, Francesca; Landini, Ida; Capaccioli, Sergio; Nobili, Stefania; Mini, Enrico; Lulli, Matteo; Monici, Monica (2015). In vitro study on the safety of near infrared laser therapy in its potential application as postmastectomy lymphedema treatment. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, vol. 151, pp. 285-296, ISSN:1011-1344 DOI Accesso ONLINE all'editore

Riganti, C; Mini, E; Nobili, S (2015). Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues.. FRONTIERS IN ONCOLOGY, vol. 5, pp. 105-107, ISSN:2234-943X DOI

Garziera, M; Bidoli, E; Cecchin, E; Mini, E; Nobili, S; Lonardi, S; Buonadonna, A; Errante, D; Pella, N; D'Andrea, M; De Marchi, F; De Paoli, A; De Mattia, E; Zanusso, C; Toffoli, G (2015). HLA-G 3’UTR +2960 14-bp INDEL (Ins/Del) polymorphism is associated to improved DFS of stage II-III CRC patients.. ANNALS OF ONCOLOGY, vol. 26, pp. 42-43, ISSN:0923-7534 DOI

Cecchin E; Perrone G; Nobili S; Polesel J; De Mattia E; Zanusso C; Petreni P; Lonardi S; Pella N; D'Andrea M; Errante D; Rizzolio F; Mazzei T; Landini I; Mini E; Toffoli G. (2015). MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin. PHARMACOGENOMICS JOURNAL, vol. 14, pp. 219-225, ISSN:1470-269X DOI

Nesi, Gabriella; Nobili, Stefania; Cai, Tommaso; Caini, Saverio; Santi, Raffaella (2015). Chronic inflammation in urothelial bladder cancer. VIRCHOWS ARCHIV, vol. 467, pp. 623-633, ISSN:0945-6317 DOI Accesso ONLINE all'editore

Mini E, Landini I, Lucarini L, Nobili S, Masini E, Moroni F (2015). In vitro cell growth inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on human tumor cell lines with defective DNA damage response pathways. In: EACR- AACR-SIC Special Conferences Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic, Florence, Italy, Giugno 20-23, 2015, American Association for Cancer Research, pp. 144-144.

Cecchin, E; Giodini, L; Buonadonna, A; Berretta, M; De Paoli, A; Scalone, S; Miolo, G; Mini, E; Nobili, S; Mazzei, T; Lonardi, S; Zagonel, V; Pella, N; Fasola, G; Tirelli, U; Montico, M; Roncato, R; Toffoli, G (2015). Pre-emptive pharmacogenetic testing implementation for chemotherapy dosage optimization: the translational experience at CRO of Aviano.. ANNALS OF ONCOLOGY, vol. 26, pp. 151-151, ISSN:0923-7534 DOI

Rigacci, L; Perrone, G; Nobili, S; Kovalchuk, S; Puccini, B; Lancia, F; Tassi, R; Brugia, M; Landini, I; Mannelli, L; Benelli, G; Napoli, C; Cencini, E; Fabbri, A; Iovino, L; Petrini, M; Birtolo, S; Melosi, A; Martini, V; Santini, S; Breschi, C; Bernardeschi, P; Bengala, C; Bosi, A; Mini, E (2015). Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study. BLOOD, vol. 126, pp. 2483-2483, ISSN:1528-0020

Nobili, S; Galletta, A; Brugia, M; Tassi, R; Petreni, P; Landini, I; Mini, E (2015). Emerging drugs in refractory colorectal cancer. FUTURE MEDICINAL CHEMISTRY, vol. 7, pp. 1491-1501, ISSN:1756-8919 DOI

Nobili S; Tassi R; Landini I; Perrone G; Napoli C; Mini E (2014). Druggable Targets in Pancreatic Adenocarcinoma. FORUM ON IMMUNOPATHOLOGICAL DISEASES AND THERAPEUTICS, vol. 5, pp. 195-214, ISSN:2151-8017

Messori L; Marchetti L; Massai L; Scaletti F; Guerri A; Landini I; Nobili S; Perrone G; Mini E; Leoni P; Pasquali M; Gabbiani C. (2014). Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents. INORGANIC CHEMISTRY, vol. 35, pp. 2395-2403, ISSN:0020-1669 DOI

Centi S; Tatini F; Ratto F; Gnerucci A; Mercatelli R; Romano G; Landini I; Nobili S; Ravalli A; Marrazza G; Mini E; Fusi F; Pini R. (2014). In vitro assessment of antibody-conjugated gold nanorods for systemic injections. JOURNAL OF NANOBIOTECHNOLOGY, vol. 12, pp. 55-65, ISSN:1477-3155 DOI Accesso ONLINE all'editore

Wolfgang J. Parak;Marek Osinski;Kenji I. Yamamoto;Francesca Tatini;Fulvio Ratto;Sonia Centi;Ida Landini;Stefania Nobili;Ewa Witort;Franco Fusi;Sergio Capaccioli;Enrico Mini;Roberto Pini (2014). Specific markers, micro-environmental anomalies and tropism: Opportunities for gold nanorods targeting of tumors in laser-induced hyperthermia. In: Colloidal Nanoparticles for Biomedical Applications IX, San Francisco, CA, USA, 1-6 Febbraio 2014, SPIE, vol. 8955, pp. 895519-1-895519-3. DOI Accesso ONLINE all'editore

Nobili S; Napoli C; Puccini B; Landini I; Perrone G; Brugia M; Benelli G; Doria M; Martelli M; Finolezzi E; Di Rocco A; Del Fava E; Rigacci L; Di Lollo S; Bosi A; Mini E. (2014). Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma. LEUKEMIA & LYMPHOMA, vol. 55, pp. 2071-2078, ISSN:1042-8194 DOI

Gamberi T; Massai L; Magherini F; Landini I; Fiaschi T; Scaletti F; Gabbiani C; Bianchi L; Bini L; Nobili S; Perrone G; Mini E; Messori L; Modesti A (2014). Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.). JOURNAL OF PROTEOMICS, vol. 103, pp. 103-120, ISSN:1874-3919 DOI

Bajetta E; Floriani I; Di Bartolomeo M; Labianca R; Falcone A; Di Costanzo F; Comella G; Amadori D; Pinto C; Carlomagno C; Nitti D; Daniele B; Mini E; Poli D; Santoro A; Mosconi S; Casaretti R; Boni C; Pinotti G; Bidoli P; Landi L; Rosati G; Ravaioli A; Cantore M; Di Fabio F; Marchet A; Rulli E; Cropalato Di Tullio M; Galli F; Biagioli E; De Simone I; Mangano S; Tonato M; Zucca E; Valsecchi MG; De Placido S; Catena L; Schiavo M; Proserpio I; Bordonaro R; Cordio S; Burrafato G; Bochicchio AM; Aieta M; Fazio N; Spada F; Amoroso V; Marini G; Soto Parra H; Novello G; Massidda B; Ionta MT; Comandè M; Venezia R; Bertolini A; Menatti E; Zanlorenzi L; Colombo A; Iop A; Bonura S; Mazza E; Viganò M; Ardizzoia A; Dell'Oro S; Lo Re G; Santeufemia D; Buonadonna A; Luisi D; Ucci G; Di Lucca G; Bonetti A; Bergamo F; Alù M; Vastola F; Marchetti P; Corsi DC; Massa E; Di Pinto G; Duro M; Oliani C; Franchini M; Inzoli A; Gebbia N; Repetto L; Rota S; Frontini L; Quadri A; De Grossi S; Cazzaniga ME; Villa F; Foa P; Ferrari D; Rabbi C; Barni S; Petrelli F; Giordano M; Luchena G; Pirovano M; Nasisi A; Catalano V; Giordan P; Zaniboni A; Leone F; Ferrario S; Beretta GD; Menichetti ET; Conte D; Mari D; Giannicola R; Pierantoni C; Luporini AG; Ragazzini MA; Tassinari D; Nicolini M; Frassineti GL; Turci D; Zumaglini F; Tamberi S; Piancastelli A; Cruciani G; Bejtja E; Minuti G; Orlandi M; Mambrini A; Ciarlo A; Cavaciocchi D; Del Monte F; Ricci S; Brunetti IM; Lencioni M; Sisani M; Sozzi P; Granetto C; Chiara S; Galetto AS; Ribecco AS; DeCensi A; Ciuffreda L; Baldini EE; Camisa R; Todeschini R; Rimassa L; Carnaghi C; Pressiani T; Rondini E; Gnoni R; Gasperoni S; Cavanna L; Palladino MA; Mattioli R; Laici G; Pucci F; Alessio MD; Bernardini I; Tomasello G; Baldino G; Rossetti R; Giaquinta S; Rijas Llimpe FL; Brandes AA; Marzola M; Competiello S; Montesarchio V; Rea A; Genua G; Licenziato M; Silvestro L; Montano M; Sarobba MG; Sanna G; Filippelli G; Dima G; Greco E; Roselli M; Natale D; Condemi G; Fumi G; Tafuto S; Masullo P; Tiberio G; de Manzoni G; Nobili S; Fiorentini G; Mazzanti R; Perrotta E; De Stefano A; Cartenì G; Otero M (2014). Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.. ANNALS OF ONCOLOGY, vol. -, pp. ---, ISSN:0923-7534 DOI

Francesca Tatini;Ida Landini;Federica Scaletti;Lara Massai;Sonia Centi;Fulvio Ratto;Stefania Nobili;Giovanni Romano;Franco Fusi;Luigi Messori;Enrico Mini;Roberto Pini (2014). Size dependent biological profiles of PEGylated gold nanorods. JOURNAL OF MATERIALS CHEMISTRY. B, vol. 2, pp. 6072-6080, ISSN:2050-750X DOI Accesso ONLINE all'editore

Guidi F; Modesti A; Landini I; Nobili S; Mini E; Bini L; Puglia M; Casini A; Dyson PJ; Gabbiani C; Messori L (2013). The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics. JOURNAL OF INORGANIC BIOCHEMISTRY, vol. 118, pp. 94-99, ISSN:0162-0134 DOI

Nobili S; Landini I; Mazzei T; Mini E (2012). Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. MEDICINAL RESEARCH REVIEWS, vol. 32, pp. 1220-1262, ISSN:0198-6325 DOI

Maiore L; Cinellu MA; Nobili S; Landini I; Mini E; Gabbiani C; Messori L (2012). Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties. JOURNAL OF INORGANIC BIOCHEMISTRY, vol. 108, pp. 123-127, ISSN:0162-0134 DOI

F.Guidi; I.Landini;M. Puglia;F.Magherini;C.Gabbiani;M.A.Cinellu;S.Nobili;T.Fiaschi;L.Bini;E.Mini;L.Messori;A.Modesti (2012). Proteomic Analysis of Ovarian Cancer Cell Responses to Cytotoxic Gold Compounds. METALLOMICS, vol. 4, pp. 307-314, ISSN:1756-5901 DOI

F. Guidi; M. Puglia; C. Gabbiani; I. Landini; T. Gamberi; D. Fregona; M.A. Cinellu; S. Nobili; E. Mini; L. Bini; P.A. Modesti; A. Modesti; L. Messori (2012). 2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds. MOLECULAR BIOSYSTEMS, vol. 8, pp. 985-993, ISSN:1742-206X DOI

Serratrice M; Cinellu MA; Maiore L; Pilo M; Zucca A; Gabbiani C; Guerri A; Landini I; Nobili S; Mini E; Messori L. (2012). Synthesis, Structural Characterization, Solution Behavior, and in Vitro Antiproliferative Properties of a Series of Gold Complexes with 2-(2'-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives. INORGANIC CHEMISTRY, vol. 51, pp. 3161-3171, ISSN:0020-1669 DOI

Mügge C; Rothenburger C; Beyer A; Görls H; Gabbiani C; Casini A; Michelucci E; Landini I; Nobili S; Mini E; Messori L; Weigand W. (2011). Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors.. DALTON TRANSACTIONS, vol. 40, pp. 2006-2016, ISSN:1477-9234 DOI

M. Vignoli; S. Nobili; C. Napoli; A.L. Putignano; M. Morganti; L. Papi; R. Valanzano; F. Cianchi; F. Tonelli; T. Mazzei; E. Mini; M. Genuardi. (2011). Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. PHARMACOLOGICAL RESEARCH, vol. 64, pp. 242-248, ISSN:1043-6618 DOI

Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E (2011). Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. INTERNATIONAL JOURNAL OF CANCER, vol. 128, pp. 1935-1945, ISSN:0020-7136 DOI

S. Nobili; L. Bruno; I. Landini; C. Napoli; P. Bechi; F. Tonelli; CA. Rubio; E. Mini; G. Nesi (2011). Genomic and genetic alterations influence the progression of gastric cancer. WORLD JOURNAL OF GASTROENTEROLOGY, vol. 17(3), pp. 290-299, ISSN:1007-9327 DOI

Maiore L; Cinellu MA; Michelucci E; Moneti G; Nobili S; Landini I; Mini E; Guerri A; Gabbiani C; Messori L. (2011). Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand.. JOURNAL OF INORGANIC BIOCHEMISTRY, vol. 105, pp. 348-355, ISSN:0162-0134 DOI

Napoli C; Nobili S; Landini I; Perrone G; Valenti A; Brugia M; Puccini B; Antognoli G; Doria M; Martelli M; Finolezzi E; Rigacci L; Di Lollo S; Bosi A; Mini E (2011). Pharmacogenomic Markers of Clinical Efficacy in a Dose-Dense Therapy Regimen (R-CHOP14) in Diffuse Large B Cell Lymphoma. BLOOD, vol. 118, pp. 2478-2478, ISSN:0006-4971

Crea F; Nobili S; Paolicchi E; Perrone G; Napoli C; Landini I; Danesi R; Mini E (2011). Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies. DRUG RESISTANCE UPDATES, vol. 14, pp. 280-296, ISSN:1368-7646 DOI

Mini E.; Nobili S.; Mazzei T. (2010). Farmaci Antineoplastici - Farmaci antiormonali. In: F. Rossi, C. Riccardi, V. Cuomo. Farmacologia - Principi di base e applicazioni terapeutiche, pp. 788-795, Torino: Edizioni Minerva Medica, ISBN:9788877116994.

Mini E.; Nobili S.; Mazzei T. (2010). Farmaci Antineoplastici - Farmaci inibitori della trasduzione del segnale. In: F. Rossi, C. Riccardi, V. Cuomo. Farmacologia - Principi di base e applicazioni terapeutiche, pp. 797-806, Torino: Edizioni Minerva Medica, ISBN:9788877116994.

Mini E.; Nobili S.; Novelli A.; Mazzei T (2010). Chemioterapici Antimicrobici - Glicopeptidi. In: F. Rossi, C. Riccardi, V. Cuomo. Farmacologia - Principi di base e applicazioni terapeutiche, pp. 672-679, Torino: Edizioni Minerva Medica, ISBN:9788877116994.

Mini E.; Nobili S.; Mazzei T. (2010). Farmaci Antineoplastici - Antimetaboliti. In: F. Rossi, C. Riccardi, V. Cuomo. Farmacologia - Principi di base e applicazioni terapeutiche, pp. 767-776, Torino: Edizioni Minerva Medica, ISBN:9788877116994.

Tonelli F; Leo F; Nobili S; Mini E; Batignani G (2010). Prognostic factors in primary and iterative surgery of colorectal liver metastases. JOURNAL OF CHEMOTHERAPY, vol. 22, pp. 358-363, ISSN:1973-9478

Nobili S; Mini E; Landini I; Gabbiani C; Casini A; Messori L. (2010). Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies.. MEDICINAL RESEARCH REVIEWS, vol. 30, pp. 550-580, ISSN:0198-6325 DOI

Caffo O; Fallani S; Marangon E; Nobili S; Cassetta MI; Murgia V; Sala F; Novelli A; Mini E; Zucchetti M; Galligioni E (2010). Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer.. CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 65, pp. 1197-1202, ISSN:0344-5704 DOI

G. Toffoli; E. Cecchin; G. Gasparini; M. D'Andrea; G. Azzarello; U. Basso; E. Mini; S. Pessa; E. De Mattia; G. Lo Re; A. Buonadonna; S. Nobili; P. De Paoli; F. Innocenti (2010). Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer. JOURNAL OF CLINICAL ONCOLOGY, vol. 28, pp. 866-871, ISSN:0732-183X DOI

Magherini F; Modesti A; Bini L; Puglia M; Landini I; Nobili S; Mini E; Cinellu MA; Gabbiani C; Messori L. (2010). Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study.. JBIC, vol. 15, pp. 573-582, ISSN:0949-8257 DOI

F. Magherini; A. Modesti; L. Bini; M. Puglia; I. Landini; S. Nobili; E. Mini; M.A. Cinellu; C. Gabbiani; L. Messori (2010). Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study.. JBIC, vol. 15, pp. 573-582, ISSN:0949-8257 DOI

Napoli C; Nobili S; Landini I; Perrone G; Puccini B; Antognoli G; Doria M; Martelli M; Finolezzi E; Rigacci L; Di Lollo S; Bosi A; Mini E (2010). Pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B cell lymphoma: preliminary results. HAEMATOLOGICA, vol. 95 (Suppl 3), pp. S95-S95, ISSN:0390-6078

Mini E; Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Mazzei T. (2009). Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer. ANNALS OF ONCOLOGY, vol. 20 (Suppl 8), pp. viii122-viii123, ISSN:0923-7534

Vignoli M; Nobili S; Napoli C; Putignano AL; Morganti M; Papi L; Valanzano R ; Cianchi F; Tonelli F; Mazzei T; Genuardi M; Mini E. (2009). Influence of TYMS gene expression and genotype on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. ANNALS OF ONCOLOGY, vol. 20 (Suppl 8), pp. viii124-viii125, ISSN:0923-7534

Mini, Enrico*; Nobili, Stefania (2009). Pharmacogenetics: Implementing personalized medicine. CLINICAL CASES IN MINERAL AND BONE METABOLISM, vol. 6, pp. 17-24, ISSN:1724-8914 Accesso ONLINE all'editore

Nobili S; Lippi D; Witort E; Donnini M; Bausi L; Mini E; Capaccioli S. (2009). Natural compounds for cancer treatment and prevention. PHARMACOLOGICAL RESEARCH, vol. 59, pp. 365-378, ISSN:1043-6618

Vignoli M; Nobili S; Napoli C; Putignano AL; Morganti M; Papi L; Valanzano R; Cianchi F; Tonelli F; Mazzei T; Mini E; Genuardi M (2009). Influence of TYMS expression and genotype on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. EUROPEAN JOURNAL OF HUMAN GENETICS, vol. 17 (suppl 2), pp. 187-187, ISSN:1018-4813

Nobili S; Mini E (2008). Alternative approaches to overcome multidrug resistance. In: Nicola Antonio Colabufo. Multidrug Resistance: Biological and Pharmaceutical Advances in Antitumour Treatment, pp. 101-139 Research Signpost, ISBN:9788130802589.

L. Bruno; G. Nesi; S. Nobili; M. Veltri; L. R. Girardi; D. Boni; C. Santomaggio; B. Neri; V. Boddi; P. Bechi; E. Mini; C. Cortesini (2008). Postoperative chemotherapy in resected gastric cancer: results of a single center experience.. JOURNAL OF CHEMOTHERAPY, vol. 20, pp. 497-502, ISSN:1120-009X Accesso ONLINE all'editore

S. Nobili; D. Checcacci; F. Filippelli; S. Del Buono; V. Mazzocchi; T. Mazzei; E. Mini (2008). Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic Acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.. JOURNAL OF CHEMOTHERAPY, vol. 20, pp. 622-631, ISSN:1120-009X

Lisa Simi; Nicola Pratesi; Marina Vignoli; Roberta Sestini; Fabio Cianchi; Rosa Valanzano; Stefania Nobili; Enrico Mini; Mario Pazzagli; Claudio Orlando (2008). High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer.. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, vol. 130, pp. 247-253, ISSN:0002-9173 DOI

Pratesi N, Simi L, Sestini R, Nobili S, Vignoli M, Landini I, Cianchi F, Valanzano R, Genuardi M, Mini E, Orlando C (2008). The clinical role of PIK3CA mutations in colorectal cancer. In: International Symposium on Cancer genotypes and Cancer phenotypes, Florence, Italy, Luglio 4-5, 2008, -, pp. 69-69.

S. NOBILI; E. MINI (2008). Overcoming multidrug resistance: alternative approaches to P-glycoprotein modulators. In: -. Multidrug resistance: biological and pharmaceutical advance in the antitumour treatment, pp. 101-139, BARI: NICOLA COLABUFO, ISBN:9788130802589. Accesso ONLINE all'editore

Napoli C, Nobili S, Morganti M, Landini I, Cianchi F, Valanzano R, Tonelli F, Mazzei T, Mini E (2008). Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer. In: International Symposium on Cancer genotypes and Cancer phenotypes, Florence, Italy, Luglio 4-5, 2008, -, pp. 62-62.

Luceri C, Castagnini C, Bigagli E, Toti S, Landini I, Napoli C, Nobili S, Mini E, Dolara P (2008). Comparative genomic hybridization study of genetic changes associated with 5-fluorouracil resistance in HCT-8 colon cancer cell lines: correlations with the expression profiles. In: International Symposium on Cancer genotypes and Cancer phenotypes, Florence, Italy, Luglio 4-5, 2008, -, pp. 53-53.

Vignoli M, Nobili S, Napoli C. Putignano AL, Morganti M, Papi L, Mini E, Genuardi M (2008). Thymidylate synthase and orotate phosphoribosyl-transferase gene expression and genotype as predictors for clinical outcome in colorectal cancer patients treated with 5-fluorouracil. In: International Symposium on Cancer genotypes and Cancer phenotypes, Florence, Italy, Luglio 4-5, 2008, -, pp. 104-104.

Landini I, Napoli C, Nobili S, Morganti M, Rigacci L, Bosi A, Mini E (2008). In vitro activity of folate antagonists against methotrexate-resistant CCRF-CEM human T-leukemia sublines and relationships with folate pathway gene expression profiles. In: International Symposium on Cancer genotypes and Cancer phenotypes, Florence, Italy, Luglio 4-5, 2008, -, pp. 61-61.

Landini I; Napoli C; Nobili S; Morganti M; Rigacci L; Bosi A; Mini E (2008). In vitro activity of folate antagonists against methotrexate-resistant CCRF-CEM human T-leukemia sublines and relationships with folate pathway gene expression profiles. HAEMATOLOGICA, vol. 93 (Suppl 2), pp. S49-S50, ISSN:0390-6078

D. Cavalieri; P. Dolara; E. Mini; C. Luceri; C. Castagnini; S. Toti; K. Maciag; C. De Filippo; S. Nobili; M. Morganti; C. Napoli; G. Tonini; M. Baccini; A. Biggeri; F. Tonelli; R. Valanzano; C. Orlando; S. Gelmini; F. Cianchi; L. Messerini; L. Luzzatto (2007). Analysis of Gene Expression Profiles Reveals Novel Correlations With the Clinical Course of Colorectal Cancer. ONCOLOGY RESEARCH, vol. 16, pp. 535-548, ISSN:0965-0407, Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL: asianfo@elsevier.com, tcb@elsevier.co.UK, INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010:

Murgia V; Caffo O; Caldara A;; Cassetta MI; Fallani S; Marangon E; Nobili S; Novelli A; Zucchetti M; d'Incalci M; Mini E; Galligioni E (2007). Plasma and intracellular pharmacokinetic (PK) study of prolonged infusion (PI) of gemcitabine (G) in combination with bolus cisplatin (C), in advanced nonsmall cell lung cancer: Preliminary results. ANNALS OF ONCOLOGY, vol. 18 suppl 11, pp. xi30-xi30, ISSN:0923-7534 DOI

Marangon E, Sala F, Caffo O, D'Incalci M, Galligioni E, Fallani S, Nobili S, Cassetta M, Mini E, Zucchetti M (2007). Administering gemcitabine as fixed-dose-rate infusion in combination with cisplatin, potentially effective target plasma concentrations are achieved in patients with advanced non-small cell lung cancer. CANCER RESEARCH, vol. 67, pp. 1560-1560, ISSN:1538-7445

S. Nobili; I. Landini; B. Giglioni; E. Mini (2006). Pharmacological strategies for overcoming multidrug resistance.. CURRENT DRUG TARGETS, vol. 7, pp. 861-879, ISSN:1389-4501 DOI Accesso ONLINE all'editore

Mini E; Nobili S; Tonelli F (2006). Terapia del carcinoma colorettale. Terapia del CCR in fase avanzata. . Enciclopedia Medica Italiana Aggiornamento III della seconda edizione Tomo 1, pp. 789-793, Torino: L. Vella - USES Edizioni Scientifiche (UTET), ISBN:9788803000533.

Mini E; Nobili S; Tonelli F. (2006). Terapia del carcinoma colorettale. Terapia medica adiuvante. . Enciclopedia Medica Italiana Aggiornamento III della Seconda Edizione - Tomo 1, pp. 787-789, Torino: L. Vella - USES Edizioni Scientifiche (UTET), ISBN:9788803000533.

A. TEMPESTINI; B. CACIAGLI; M. MORGANTI; E. WITORT; S. NOBILI; L. PAPUCCI; N. SCHIAVONE; M. DONNINI; I. LANDINI; A. LAPUCCI; F. PERNA; M. LULLI; T. MAZZEI; A. SOBRERO; E. MINI; S. CAPACCIOLI (2006). MOLECULAR CHARACTERIZATION OF ESTABLISHED HUMAN COLON CARCINOMA CELL LINES (HCT-8) MADE RESISTANT TO 5-FLUOROURACIL BY DIFFERENT SELECTION SCHEDULES. ONCOLOGY RESEARCH, vol. 16, pp. 143-156, ISSN:0965-0407, Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL: asianfo@elsevier.com, tcb@elsevier.co.UK, INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010:

E. Mini; S. Nobili; B. Caciagli; I. Landini; T. Mazzei (2006). Cellular pharmacology of gemcitabine.. ANNALS OF ONCOLOGY, vol. 17 Suppl 5, pp. 7-12, ISSN:0923-7534 DOI Accesso ONLINE all'editore

E. Mini; S. Nobili; T. Mazzei (2005). Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale. In: F. Rossi, V. Cuomo, C. Riccardi. Farmacologia - Principi di base e applicazioni terapeutiche, pp. 722-726, Torino: Edizioni Minerva Medica, ISBN:9788877114976.

E. Mini; S. Nobili; T. Mazzei (2005). Farmaci antineoplastici - Antimetaboliti. In: F. Rossi, C. Riccardi, V. Cuomo. Farmacologia - Principi di base e applicazioni tecniche, pp. 691-704, Torino: Edizioni Minerva Medica, ISBN:9788877114976.

E. Mini; S. Nobili (2005). Febbre. In: G. Lelli. Sintomi "segnale" in oncologia clinica fisiopatologia, diagnosi e terapia, pp. 41-50, Ferrara: Monduzzi Editore, ISBN:9788832360233.

E. Mini; S. Nobili; T. Mazzei (2005). Farmaci antineoplastici - Farmaci antiormonali. In: F. Rossi, V. Cuomo, G. Riccardi. Farmacologia - Principi di base e applicazioni terapeutiche, pp. 713-720, Torino: Edizioni Minerva Medica, ISBN:9788877114976.

Morganti M; Ciantelli M; Giglioni B; Putignano AL; Nobili S; Papi L; Landini I; Napoli C; Valanzano R; Cianchi F; Boddi V; Tonelli F; Cortesini C; Mazzei T; Genuardi M; Mini E (2005). Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. EUROPEAN JOURNAL OF CANCER, vol. 41, pp. 2176-2183, ISSN:0959-8049 DOI

E.Mini; S.Nobili; A.Novelli; T.Mazzei (2005). Glicopeptidi. In: F.Rossi, V.Cuomo, C.Riccardi. Farmacologia: principi di base e applicazioni terapeutiche, pp. 611-618, Torino.: Edizioni Minerva Medica., ISBN:9788877114976.

Nobili S; Del Buono S; Mazzocchi V; Filippelli F; Checcacci D; Giglioni B; Mazzei T; Mini E (2004). Bimonthly chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT11), infusional 5-fluorouracil/folinic acid (FU/FA) in patients with metastatic colorectal cancer pretreated with CPT11- or OHP-based CHT. ANNALS OF ONCOLOGY, vol. 15 suppl 2, pp. 65-65, ISSN:0923-7534

Morganti M; Ciantelli M; Giglioni B; Putignano AL; Nobili S; Papi L; Landini I; Napoli C; Valanzano R; Cianchi F; Boddi V; Tonelli F; Cortesini C; Mazzei T; Genuardi M; Mini E. (2004). Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients. ANNALS OF ONCOLOGY, vol. 15, pp. 61-61, ISSN:0923-7534

Morganti M, Ciantelli M, Giglioni B, Putignano AL, Nobili S, Papi L, Landini I, Napoli C, Valanzano R, Cianchi F, Boddi V, Tonelli F, Cortesini C, Mazzei T, Genuardi M, Mini E (2004). Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphysms in primary colorectal cancer patients.. CANCER RESEARCH, vol. 67, pp. 866-867, ISSN:1538-7445

Morganti, M; Ciantelli, M; Giglioni, B; Putignano, Al; Nobili, S; Papi, L; Landini, I; Napoli, C; Valanzano, R; Cianchi, F; Boddi, V; Tonelli, F; Cortesini, C; Mazzei, T; Genuardi, M; Mini, E. (2004). Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients. JOURNAL OF CHEMOTHERAPY, vol. 16 (Suppl. 1), pp. 205-205, ISSN:1973-9478

R.Mazzanti;AL.Giallombardo;E.Mini;S.Nobili;B.Neri;U.Arena; P.Pantaleo;V.Fabbroni;M.Ghilardi;R.Gattai;L.Bandettini (2004). Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study.. DIGESTIVE AND LIVER DISEASE, vol. 36, pp. 278-285, ISSN:1590-8658 DOI

Nobili S; Del Buono S; Mazzocchi V; Filippelli F; Giglioni B; Mazzei T; Mini E (2004). Biweekly (BW) chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT11), infusional 5-fluorouracil/folinic acid (FU/FA) in patients (PTS) with metastatic colorectal cancer (MCRC) pretreated with CPT11- or OHP-based CHT.. JOURNAL OF CHEMOTHERAPY, vol. 16 (suppl 1), pp. 213-213, ISSN:1120-009X

Mini E.; Nobili S; Del Buono S; Mazzocchi V; Filippelli F; Giglioni B; Mazzei T (2004). Biweekly (BW) chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT11), infusional 5-fluorouracil/folinic acid (FU/FA) in patients (pts) with metastatic colorectal cancer (MCRC) pretreated with CPT11- or OHP-based CHT. JOURNAL OF CLINICAL ONCOLOGY, vol. 22, pp. 3065-3065, ISSN:0732-183X

Di Fabio F; Mini E; Gentile AL; Nobili S; Angelelli B; Giaquinta S; Rojas Llimpe FL; Pinto C;Mazzei T; Martoni A (2004). Neurotoxicity of oxaliplatin (OXA) in advanced colorectal cancer (ACRC) chemotherapy: evaluation of three consecutive prospective studies. ANNALS OF ONCOLOGY, vol. 15 suppl 2, pp. 58-58, ISSN:0923-7534

Nobili S; Mazzocchi V; Del Buono S.; Scicolone S; Giglioni B; Mazzei T; Mini E (2003). Biweekly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. JOURNAL OF CHEMOTHERAPY, vol. 15 (Suppl 1), pp. 69-69, ISSN:1973-9478

Mini E; Nobili S; Mazzocchi V; Del Buono S; Scicolone S; Giglioni B; Mazzei T (2003). Biweekly (BW) chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT-11), infusional 5-fluorouracil/folinic acis (FU/FA) in patients (PTS) with metastatic colorectal cancer (MCRC) pretreated with CPT-11- or OHP-based CHT. JOURNAL OF CLINICAL ONCOLOGY, vol. 22, pp. 1503-1503, ISSN:0732-183X

Morganti M; Ciantelli M; Giglioni B; Nobili S.; Papi L.; Landini I.; Napoli C.; Valanzano R.; Cianchi F; Boddi V.; Tonelli F; Cortesini C; Mazzei T; Genuardi M; Mini E (2003). Thymidylate Synthase (TS) mRNA expression and TS gene promoter polymorphism in primary colorectal cancer (CRC) patients (PTS) receiving post-operative fluorouracil (5-FU)-based chemotherapy (CT). JOURNAL OF TUMOR MARKER ONCOLOGY, vol. 18, pp. 171-171, ISSN:0886-3849

Gentile AL; Pinto C; Mini E; Nobili S; Di Fabio F; Mazzei T; Martoni A (2003). Neurotoxicity in advanced colorectal cancer (ACRC) patients treated with three different oxaliplatin (OXA) regimens. ANNALS OF ONCOLOGY, vol. 14, pp. 49-49, ISSN:0923-7534

Landini I; Carotti S; Caciagli B; Morganti M; Napoli C; Nobili S; Giglioni B; Boddi V; Mazzei T; Mini E (2003). Sequence-dependent interactions between oxaliplatin and 5-fluorouracil in human colon carcinoma cell lines. JOURNAL OF CHEMOTHERAPY, vol. 15 (Suppl 1), pp. 36-36, ISSN:1973-9478

A. MARTONI; E. MINI; C. PINTO; AL. GENTILE; S. NOBILI; P. DENTICO; A. MARINO; S. SCICOLONE; B. ANGELELLI; T. MAZZEI (2003). OXALIPLATIN PLUS RALTITREXED IN THE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER: A PHASE II STUDY. ANTICANCER RESEARCH, vol. 23, pp. 687-691, ISSN:0250-7005, International Institute of Anticancer Research:John G Delinassios, 1st Km Kapandritiou-Kalamou Road, Kapandriti Attiki 19014 Greece:011 30 2 2950 53389, 011 30 2950 52945, EMAIL: journals@iiar-anticancer.org, INTERNET: http://www.iiar-anticancer.org, Fax: 011 30 2 2950 53389, 011 30 2 2950 52945:

Martoni A.; Mini E.; Pinto C.; Gentile AL; Nobili S; Marino A; Dentico P; Angelelli B; Scicolone S; Piana E; Mazzei T (2002). Phase II study of oxaliplatin (OHP) and raltitrexed (RTX) in chemonaive and pretreated advanced colorectal cancer (ACRC) patients. JOURNAL OF CLINICAL ONCOLOGY, vol. 21, pp. 689-689, ISSN:0732-183X

Mini E.; Morganti M.; Napoli C.; Valanzano R.; Cianchi F.; Messerini A; Nobili S; Boddi V; Tonelli F; Cortesini C; Toffoli G; Mazzei T (2002). The role of thymidylate synthase (TS) expression in prognosis and outcome of 5-fluorouracil (5-FU)-based chemotherapy in patients (pts) with colorectal cancer (CC). JOURNAL OF CLINICAL ONCOLOGY, vol. 21, pp. 2266-2266, ISSN:0732-183X

Stefania Nobili (2002). Analisi dell'espressione di geni coinvolti nella resistenza al 5-fluorouracile nel carcinoma colorettale. (Tutor: Teresita mazzei)

Mazzei T.; Carotti S.; Landini I.; Caciagli B.; Nobili S.; Mini E (2002). Sequence-dependent interactions between oxaliplatin (OHP) and 5-fluorouracil (5-FU) in human colon carcinoma cell lines. JOURNAL OF CLINICAL ONCOLOGY, vol. 21, pp. 2183-2183, ISSN:0732-183X

Mini E, Caciagli B, Carotti S, Landini I, Morganti M, Nobili S, Coronnello M, Toffoli G, Jansen G, Peters GJ, Priest DG, Mazzei T (2002). Mechanisms of methotrexate (MTX) resistance in human colon carcinoma cells DLD-1. In: 93rd Annual Meeting American Association for Cancer Research (AACR), San Francisco, CA, USA, April 6-10, 2002., Waverly Press, pp. 3864-3864.

Carotti S.; Landini I.; Caciagli B.; Nobili S.; Mazzei T.; Mini E (2001). Sequence-dependent interactions between oxaliplatin and 5-fluorouracil in human colon carcinoma cell lines. ANNALS OF ONCOLOGY, vol. 12 suppl 4, pp. 86-86, ISSN:0923-7534

A. Martoni; E. Mini; C. Pinto; S. Nobili; A. L. Gentile; P. Dentico; B. Angelelli; S. Scicolone; E. Piana; T. Mazzei (2001). Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma.. ANNALS OF ONCOLOGY, vol. 12, pp. 519-524, ISSN:0923-7534 Accesso ONLINE all'editore

E. Mini; F. Grassi; P. Cherubino; S. Nobili; P. Periti (2001). Preliminary results of a survey of the use of antimicrobial agents as prophylaxis in orthopedic surgery.. JOURNAL OF CHEMOTHERAPY, vol. 13 Spec No 1, pp. 73-79, ISSN:1120-009X Accesso ONLINE all'editore

Caciagli B, Carotti S, Landini I, Morganti M, Nobili S, Coronnello M, Jansen G, Peters GJ, Toffoli G, Priest DG, Mini E (2001). Mechanisms of methotrexate (MTX) resistance in human colon carcinoma cells DLD-1. In: 22nd Meeting of EORTC-PAMM Group, Verona, Italy, Gennaio 31 – Febbraio 3, 2001, -, pp. 42-42.

Pinto C.; Mini E.; Gentile A.L.; Nobili S.; Marino A.; Dentico P.; Angelelli B.; Scicolone S.; Piana E.; Iovi F.; Mazzei T.; Martoni A (2001). Oxaliplatin (OHP) and raltitrexed (RTX) in advanced colorectal cancer (ACRC) patients: a phase II study. JOURNAL OF CLINICAL ONCOLOGY, vol. 20, pp. 2204-2204, ISSN:0732-183X

Mini E.; Caciagli B.; Carotti S.; Landini I.; Morganti M.; Nobili S.; Mazzei T.; Toffoli G.; Jansen G.; Peters G.J.; Priest D.J (2001). Multiple mechanisms of methotrexate (MTX) resistance in human colon carcinoma cells DLD-1.. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 17, pp. S20-S20, ISSN:0924-8579

Mini E.; Caciagli B.; Carotti S.; Landini I.; Morganti M.; Nobili S.; Coronnello M.; Toffoli G.; Jansen G.; Peters G.J.; Priest D.G.; Mazzei T (2001). Multiple mechanisms of methotrexate (MTX) resistance in human colon carcinoma cells DLD-1. PHARMACOLOGICAL RESEARCH, vol. 43 suppl A, pp. 133-133, ISSN:1043-6618

Mini E.; Pinto C.; Gentile A.L.; Marino A.; Angelelli B.; Piana E.; Martoni A.; Nobili S.; Dentico P.; Scicolone S.; Mazzei T (2001). Oxaliplatin (OHP) and raltitrexed (RTX) in advanced colorectal cancer (ACRC) patients (PTS): preliminary results of a phase II study. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 17, pp. S21-S21, ISSN:0924-8579

Pinto C.; Mini E.; Gentile A.L.; Marino A.; Nobili S.; Dentico P.; Angelelli B.; Carpani B.; Scicolone S.; Mazzei T.; Martoni A (2001). Neurotoxicity in patients treated with oxaliplatin (OHP) combination chemotherapy for advanced colorectal cancer (ACRC) in two consecutive phase II studies. ANNALS OF ONCOLOGY, vol. 12 suppl 4, pp. 8-8, ISSN:0923-7534

Pinto C; Mini E; Petronelli A; Dentico P; Piana E; Nobili S; Gentile A; Scicolone S; Mazzei T; Martoni A (2000). Oxaliplatin (OHP) and Protracted 5-Fluorouracil (5 FU) Infusion in Pretreated Metastatic Colorectal Cancer (MCRC) Patients: A Phase II Study. JOURNAL OF CLINICAL ONCOLOGY, vol. 19, pp. 1172-1172, ISSN:0732-183X

Mini E.; Pinto C.; Angelelli B.; Dentico P.; Piana E.; Nobili S.; Gentile A.L.; Scicolone S.; Mazzei T.; Martoni A (2000). Phase II study of oxaliplatin (OHP) and protracted 5-fluorouracil (5FU) infusion in pretreated metastatic colorectal cancer (MCRC) patients. ANNALS OF ONCOLOGY, vol. 11 suppl 2, pp. 73-73, ISSN:0923-7534

Napoli C.; Morganti P.; Bruno L.; Nobili S.; Cortesini C.; Mazzei T.; Mini E (2000). Preliminary results of thymidylate synthase (TS) and folylpolyglutamate synthetase (FPGS) gene expression analysis by polymerase chain reaction (PCR) in gastric cancer patients (PTS). ANNALS OF ONCOLOGY, vol. 11, pp. 16-16, ISSN:0923-7534

Napoli C.; Morganti M.; Bruno L.; Nobili S.; Cortesini C.; Mazzei T.; Mini E (2000). Expression of thymidylate synthase (TS) and folylpolyglutamate synthetase (FPGS) genes by polymerase chain reaction (PCR) in gastric cancer patients (PTS): preliminary results. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, pp. 249-249, ISSN:0306-5251

E. Mini; S. Nobili; P. Periti (2000). Does surgical prophylaxis with teicoplanin constitute a therapeutic advance?. JOURNAL OF CHEMOTHERAPY, vol. 12 Suppl 5, pp. 40-55, ISSN:1120-009X

Mini E; Mazzei T; Nobili S; Periti P (1999). High-dose intravenous quinolones: efficacy and safety in lower respiratory tract infection therapy. JOURNAL OF CHEMOTHERAPY, vol. 11 (Suppl 2), pp. 52-52, ISSN:1973-9478

Caciagli B.; Carotti S.; Morganti M.; Landini I.; Nobili S.; Mazzei T.; Toffoli G.; Mini E (1999). Preliminary characterization of methotrexate (MTX) resistance mechanisms in human colon carcinoma cells DLD-1. PHARMACOLOGICAL RESEARCH, vol. 39, pp. 99-99, ISSN:1043-6618

Caciagli B.; Carotti S.; Morganti M.; Landini I.; Nobili S.; Mazzei T.; Toffoli G.; Mini E (1999). Preliminary characterization of methotrexate (MTX) resistance mechanisms in human colon carcinoma cells DLD-1. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 44, pp. 162-162, ISSN:0305-7453

Mazzei T.; Bellacci A.; Pesciullesi A.; Galli A.; Carlà V.; Nobili S.; Caciagli B.; Pace M.; Mini E (1998). Pharmacokinetic monitoring of melphalan (L-PAM) during hyperthermic perfusion in patients (PTS) with melanoma of the limbs. JOURNAL OF CLINICAL ONCOLOGY, vol. 17, pp. 228-228, ISSN:0732-183X

Pesciullesi A.; Bellacci A.; Carla V.; Galli A.; Nobili S.; Mini E.; Pace M.; Mazzei T. (1997). Pharmacokinetics of melphalan (L-PAM) during hyperthermic perfusion in patients with melanoma of the limbs. PHARMACOLOGICAL RESEARCH, vol. 35, pp. 232-233, ISSN:1043-6618

Pesciullesi A.; Bellacci A.; Carlà V.; Galli A.; Nobili S.; Mini E.; Pace M.; Mazzei T (1997). Pharmacokinetic monitoring of melphalan (L-PAM) during hyperthermic perfusion in patients with melanoma of the limbs. PHARMACOLOGICAL RESEARCH, vol. 35, pp. 232-233, ISSN:1043-6618

E. Mini; S. Nobili; P. Periti (1997). Methicillin-resistant staphylococci in clean surgery. Is there a role for prophylaxis?. DRUGS, vol. 54 Suppl 6, pp. 39-52, ISSN:0012-6667

Tonelli F, Periti P, Mazzei T, Mini E, Ficari F, Valanzano R, Nobili S, Mazzoni P (1995). Adjuvant chemotherapy with 5-fluorouracil (5-FU) and folinic acid (L-LV) for colorectal carcinoma: preliminary results of a randomized multicenter study of the Gruppo Cooperativo Oncologico Tosco-Umbro (GCOTU). In: 15th Anniversary International Congress. Colorectal cancer: from Gene to Cure, Amsterdam, The Netherlands, Febraio 9-11, 1995, -, pp. 49-49.

Stefania NOBILI

Curriculum

Dr. Stefania Nobili obtained the Pharm.D. degree in 1989 (“La Sapienza” University, Rome), the specialization in Applied Pharmacology in 1997 (University of Florence) and the Ph.D. in Chemotherapy in 2002 (University of Milan).

Since October 2022, Dr. Nobili is Assistant Professor in Pharmacology (ex BIO/14, now BIOS-11A) (RTD B) at the NEUROFARBA Department of the University of Florence.

From 2020 to 2022 she was Assistant Professor in Pharmacology (RTD B, BIO/14) at the “G. d’Annunzio” University of Chieti-Pescara (Chieti) and in the previous years (2007-2019) was Assistant Professor in Pharmacology (RTD and RTD-A BIO/14) at the University of Florence.

Among the major achievements in recent years there are the national scientific qualification (ASN) as Full Professor in Pharmacology (BIOS-11A) (2023) and the winning of an Assistant Professor position (RTD-B) in Pharmacology (BIO/14) at the University of Genoa (2021). Also, Dr. Nobili possesses the ASN as Associate Professor in Pharmacology (2014 and 2018), as Associate Professor for the sector 06/N1 Sciences of the Health Professions and Applied Medical Technology, SSD MED/46 Technical Sciences of Laboratory Medicine (2018) and as Associate Professor for the sector 06/D3 Hematological Diseases, Oncology and Rheumatology, SSD MED/06 Oncology (2018).

She received the following awards: “Alberico Benedicenti” Award for Pharmacology and Toxicology (Italian Society of Pharmacology, 2013); “Emilio Trabucchi” Award (Italian Society of Chemotherapy, 2009).

Dr. Nobili is a member of the Excellence Commission of the NEUROFARBA Department (Department of Excellence 2023-2027) and a member of the Scientific Committee of the Biomedical Library of the University of Florence.

She is member of the Italian Society of Pharmacology (SIF) and the following three SIF Working Groups: Cancer Pharmacology, Pharmacogenetics, Pediatric Pharmacology.

She is the Secretary of the Italian Society of Chemotherapy (SIC) and the Liaison between the PathoBiology Group (PBG) and the Pharmacology and Molecular Mechanisms (PAMM) Group of the European Organization for Research and Treatment of Cancer (EORTC).

Dr. Nobili has supervised several students at the University of Florence and she is currently supervising or co-supervising two Ph.D. students.

She is a member of the Board of the Ph.D course in the Area of Drug and Innovative Treatments, University of Florence. She currently teaches pharmacology at students attending the Dentistry degree; pharmacology and toxicology at students attending the Nursing degree; pharmacology at the “Clinical Pharmacology and Toxicology” and “Medical Oncology” Specialty Schools (University of Florence). Main teaching activity in the past years was represented by chemotherapy courses to students in Pharmacy (University of Florence), pharmacology courses to students in Nursing (University of Florence and “G. d’Annunzio” University of Chieti-Pescara), students in Biotechnologies, students attending the Hospital Pharmacy specialty schools and several medical specialty schools at the University of Florence and at the University of Chieti-Pescara.

She regularly acts as invited speaker at national and international meetings (25 invited lectures).

Dr. Nobili obtained funds from institutions (e.g. University of Florence, G. d’Annunzio” University of Chieti-Pescara, ANVUR-MIUR) and local, national/international agencies and foundations (EUniWell, Tuscany Region, Fondazione Cassa di Risparmio di Firenze, ThermoFisher scientific (US), Giacomo ODV).

She acts as Section Editor for Pharmacology and Pharmaceutics for All Life journal (Taylor & Francis, UK), as Associate Editor for BMC Pharmacology & Toxicology (Springer Nature, UK), Frontiers in Pharmacology (Frontiers Media SA, Switzerland), Frontiers in Oncology (Frontiers Media SA, Switzerland), as Editor for Archives of Natural and Medicinal Chemistry (Gavin Publishers, USA). Also, Dr. Nobili regularly reviews papers on cancer pharmacology and medical oncology.

She acts and/or acted as ANVUR evaluator and as evaluator of projects submitted to national (University of Modena and Reggio Emilia) and international agencies (e.g. H2020 European Projects, Bruxelles, Belgium; H2020-Marie Skłodowska-Curie COFUND Programme (NL); “La Caixa” Foundation, Barcelona, Spain; Koningin Wilhelmina Fonds (KWF) Dutch Cancer Society, The Netherlands; Natural Sciences and Engineering Research Council of Canada, Ottawa, Canada).

Her research interests are focused on preclinical and clinical pharmacology of anticancer drugs, in particular cancer pharmacogenetics and pharmacogenomics, tumor drug resistance. Antimicrobial agents with a focus on antibiotics, also represent a field of interest.

She is responsible for the datasets GSE122246 and GSE186441 available on the NCBI GEO (Gene Expression Omnibus) website.

Dr. Nobili has published more than 100 international peer-reviewed articles and 35 book chapters (Scopus total citations 4860; HI 34).